LAMEA Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

The Latin America, Middle East and Africa Guillain-Barre Syndrome Market would witness market growth of 6.2% CAGR during the forecast period (2023-2030).

The Brazil market dominated the LAMEA Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $15,320.9 Thousands by 2030. The Argentina market is registering a CAGR of 7.1% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 5.9% during (2023 - 2030).

Cerebrospinal fluid (CSF) analysis lumbar puncture is performed to obtain CSF samples for analysis, including cell counts, protein levels, and the presence of inflammatory markers such as elevated protein levels without an increase in white blood cells, indicative of albumin cytologic dissociation, a hallmark of GBS.

Additionally, magnetic resonance imaging (MRI) of the spine and nerve roots may reveal characteristic findings such as nerve root enhancement, nerve enlargement, or spinal cord abnormalities, supporting the diagnosis of GBS and ruling out other neurological conditions.

The World Health Organization (WHO) reports that 130 suspected cases of GBS were reported in Peru between June 10, 2023, and July 15, 2023. 44 of these cases have been verified. The number of instances observed has increased more than anticipated. Additionally, 231 probable GBS cases were reported in Peru between epidemiological weeks 1 and 28 (until July 15, 2023). Thus, the rising aging population and increasing healthcare expenditure in the LAMEA region propel the market’s growth.

Free Valuable Insights: The Worldwide Guillain-Barre Syndrome Market is Projected to reach USD 852.2 Million by 2030, at a CAGR of 4.6%

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

• F.Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• PTC, Inc.
• AstraZeneca PLC
• Novartis AG
• Novo Nordisk A/S
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Merck & Co., Inc.
• Bristol Myers Squibb Company

LAMEA Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

• Intravenous Immunoglobulin
• Plasma Exchange
• Others

By Route Of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Guillain-Barre Syndrome Market, by Therapeutics
1.4.2 LAMEA Guillain-Barre Syndrome Market, by Route Of Administration
1.4.3 LAMEA Guillain-Barre Syndrome Market, by Distribution Channel
1.4.4 LAMEA Guillain-Barre Syndrome Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. LAMEA Guillain-Barre Syndrome Market by Therapeutics
4.1 LAMEA Intravenous Immunoglobulin Market by Country
4.2 LAMEA Plasma Exchange Market by Country
4.3 LAMEA Others Market by Country

Chapter 5. LAMEA Guillain-Barre Syndrome Market by Route Of Administration
5.1 LAMEA Parenteral Market by Country
5.2 LAMEA Oral Market by Country

Chapter 6. LAMEA Guillain-Barre Syndrome Market by Distribution Channel
6.1 LAMEA Hospital Pharmacies Market by Country
6.2 LAMEA Retail Pharmacies Market by Country
6.3 LAMEA Others Market by Country

Chapter 7. LAMEA Guillain-Barre Syndrome Market by Country
7.1 Brazil Guillain-Barre Syndrome Market
7.1.1 Brazil Guillain-Barre Syndrome Market by Therapeutics
7.1.2 Brazil Guillain-Barre Syndrome Market by Route Of Administration
7.1.3 Brazil Guillain-Barre Syndrome Market by Distribution Channel
7.2 Argentina Guillain-Barre Syndrome Market
7.2.1 Argentina Guillain-Barre Syndrome Market by Therapeutics
7.2.2 Argentina Guillain-Barre Syndrome Market by Route Of Administration
7.2.3 Argentina Guillain-Barre Syndrome Market by Distribution Channel
7.3 UAE Guillain-Barre Syndrome Market
7.3.1 UAE Guillain-Barre Syndrome Market by Therapeutics
7.3.2 UAE Guillain-Barre Syndrome Market by Route Of Administration
7.3.3 UAE Guillain-Barre Syndrome Market by Distribution Channel
7.4 Saudi Arabia Guillain-Barre Syndrome Market
7.4.1 Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics
7.4.2 Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration
7.4.3 Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel
7.5 South Africa Guillain-Barre Syndrome Market
7.5.1 South Africa Guillain-Barre Syndrome Market by Therapeutics
7.5.2 South Africa Guillain-Barre Syndrome Market by Route Of Administration
7.5.3 South Africa Guillain-Barre Syndrome Market by Distribution Channel
7.6 Nigeria Guillain-Barre Syndrome Market
7.6.1 Nigeria Guillain-Barre Syndrome Market by Therapeutics
7.6.2 Nigeria Guillain-Barre Syndrome Market by Route Of Administration
7.6.3 Nigeria Guillain-Barre Syndrome Market by Distribution Channel
7.7 Rest of LAMEA Guillain-Barre Syndrome Market
7.7.1 Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics
7.7.2 Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration
7.7.3 Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel

Chapter 8. Company Profiles
8.1 F. Hoffmann-La Roche Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 SWOT Analysis
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional & Segmental Analysis
8.2.4 Research & Development Expense
8.2.5 SWOT Analysis
8.3 PTC, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 SWOT Analysis
8.5 Novartis AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.6 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Takeda Pharmaceutical Company Limited
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Bayer AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.6 SWOT Analysis
8.10. Bristol Myers Squibb Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 SWOT Analysis

TABLE 1 LAMEA Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 2 LAMEA Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 3 LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 4 LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 5 LAMEA Intravenous Immunoglobulin Market by Country, 2019 - 2022, USD Thousands
TABLE 6 LAMEA Intravenous Immunoglobulin Market by Country, 2023 - 2030, USD Thousands
TABLE 7 LAMEA Plasma Exchange Market by Country, 2019 - 2022, USD Thousands
TABLE 8 LAMEA Plasma Exchange Market by Country, 2023 - 2030, USD Thousands
TABLE 9 LAMEA Others Market by Country, 2019 - 2022, USD Thousands
TABLE 10 LAMEA Others Market by Country, 2023 - 2030, USD Thousands
TABLE 11 LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 12 LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 13 LAMEA Parenteral Market by Country, 2019 - 2022, USD Thousands
TABLE 14 LAMEA Parenteral Market by Country, 2023 - 2030, USD Thousands
TABLE 15 LAMEA Oral Market by Country, 2019 - 2022, USD Thousands
TABLE 16 LAMEA Oral Market by Country, 2023 - 2030, USD Thousands
TABLE 17 LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 18 LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 19 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 20 LAMEA Hospital Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 21 LAMEA Retail Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 22 LAMEA Retail Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 23 LAMEA Others Market by Country, 2019 - 2022, USD Thousands
TABLE 24 LAMEA Others Market by Country, 2023 - 2030, USD Thousands
TABLE 25 LAMEA Guillain-Barre Syndrome Market by Country, 2019 - 2022, USD Thousands
TABLE 26 LAMEA Guillain-Barre Syndrome Market by Country, 2023 - 2030, USD Thousands
TABLE 27 Brazil Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 28 Brazil Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 29 Brazil Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 30 Brazil Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 31 Brazil Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 32 Brazil Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 33 Brazil Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 34 Brazil Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 35 Argentina Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 36 Argentina Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 37 Argentina Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 38 Argentina Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 39 Argentina Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 40 Argentina Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 41 Argentina Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 42 Argentina Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 43 UAE Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 44 UAE Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 45 UAE Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 46 UAE Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 47 UAE Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 48 UAE Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 49 UAE Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 50 UAE Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 51 Saudi Arabia Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 52 Saudi Arabia Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 53 Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 54 Saudi Arabia Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 55 Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 56 Saudi Arabia Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 57 Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 58 Saudi Arabia Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 59 South Africa Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 60 South Africa Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 61 South Africa Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 62 South Africa Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 63 South Africa Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 64 South Africa Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 65 South Africa Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 66 South Africa Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 67 Nigeria Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 68 Nigeria Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 69 Nigeria Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 70 Nigeria Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 71 Nigeria Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 72 Nigeria Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 73 Nigeria Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 74 Nigeria Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 75 Rest of LAMEA Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 76 Rest of LAMEA Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 77 Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 78 Rest of LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 79 Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 80 Rest of LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 81 Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 82 Rest of LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 83 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 84 Key Information – Pfizer, Inc.
TABLE 85 key Information – PTC, Inc.
TABLE 86 KEY INFORMATION – AstraZeneca PLC
TABLE 87 Key Information – Novartis AG
TABLE 88 Key Information – Novo Nordisk A/S
TABLE 89 Key Information – Takeda Pharmaceutical Company Limited
TABLE 90 Key Information – Bayer AG
TABLE 91 Key Information - Merck & Co., Inc.
TABLE 92 Key Information – Bristol Myers Squibb Company

List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Guillain-Barre Syndrome Market, 2019 - 2030, USD Thousands
FIG 3 Key Factors Impacting Guillain-Barre Syndrome Market
FIG 4 Porter’s Five Forces Analysis – Guillain-Barre Syndrome Market
FIG 5 LAMEA Guillain-Barre Syndrome Market share by Therapeutics, 2022
FIG 6 LAMEA Guillain-Barre Syndrome Market share by Therapeutics, 2030
FIG 7 LAMEA Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2030, USD Thousands
FIG 8 LAMEA Guillain-Barre Syndrome Market share by Route Of Administration, 2022
FIG 9 LAMEA Guillain-Barre Syndrome Market share by Route Of Administration, 2030
FIG 10 LAMEA Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2030, USD Thousands
FIG 11 LAMEA Guillain-Barre Syndrome Market share by Distribution Channel, 2022
FIG 12 LAMEA Guillain-Barre Syndrome Market share by Distribution Channel, 2030
FIG 13 LAMEA Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2030, USD Thousands
FIG 14 LAMEA Guillain-Barre Syndrome Market share by Country, 2022
FIG 15 LAMEA Guillain-Barre Syndrome Market share by Country, 2030
FIG 16 LAMEA Guillain-Barre Syndrome Market by Country, 2019 - 2030, USD Thousands
FIG 17 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 18 SWOT Analysis: Pfizer, Inc.
FIG 19 SWOT Analysis: PTC, Inc.
FIG 20 SWOT Analysis: AstraZeneca PLC
FIG 21 SWOT Analysis: Novartis AG
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 SWOT Analysis:Takeda Pharmaceutical Company Limited
FIG 24 Swot Analysis: Bayer AG
FIG 25 SWOT Analysis: Merck & Co., Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company